Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation

Journal of the American Society of Nephrology

Volumn 25, Issue 4, 2014, Pages 737-744

  Tasaki, Masayuki ^a   Shimizu, Akira ^a   Hanekamp, Isabel ^a   Torabi, Radbeh ^a   Villani, Vincenzo ^a   Yamada, Kazuhiko ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RITUXIMAB; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE ACID LIKE 3B; UNCLASSIFIED DRUG; URINARY TRACT AGENT; GALACTOSYLTRANSFERASE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CELL CULTURE; CELL DEATH; CELL DISRUPTION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG PROTEIN BINDING; EMBRYO; GALACTOSYLTRANSFERASE GENE KNOCKOUT PIG; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; NONHUMAN; PODOCYTE; POSTOPERATIVE PERIOD; PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; SWINE; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CELLS, CULTURED; GALACTOSYLTRANSFERASES; KIDNEY TRANSPLANTATION; PAPIO; PODOCYTES; PROTEINURIA; SPHINGOMYELIN PHOSPHODIESTERASE; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84901465008     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013040363     Document Type: Article

References (25)

1. Cozzi E, White DJ: The generation of transgenic pigs as potential organ donors for humans. Nat Med 1: 964-966, 1995
2. McGregor CG, Davies WR, Oi K, Teotia SS, Schirmer JM, Risdahl JM, Tazelaar HD, Kremers WK, Walker RC, Byrne GW, Logan JS: Cardiac xenotransplantation: Recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 130: 844-851, 2005
3. Kolber-Simonds D, Lai L, Watt SR, Denaro M, Arn S, Augenstein ML, Betthauser J, Carter DB, Greenstein JL, Hao Y, Im GS, Liu Z, Mell GD, MurphyCN, Park KW, Rieke A, Ryan DJ, Sachs DH, Forsberg EJ, Prather RS, Hawley RJ: Production of alpha-1, 3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 101: 7335-7340, 2004
4. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im GS, Samuel M, Bonk A, Rieke A, Day BN, MurphyCN, Carter DB, Hawley RJ, Prather RS: Production of alpha-1, 3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295: 1089-1092, 2002
5. Yamada K, Yazawa K, Shimizu A, Iwanaga T, Hisashi Y, Nuhn M, O'Malley P, Nobori S, Vagefi PA, Patience C, Fishman J, Cooper DK, Hawley RJ, Greenstein J, Schuurman HJ, Awwad M, Sykes M, Sachs DH: Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1, 3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 11: 32-34, 2005
6. Griesemer AD, Hirakata A, Shimizu A, Moran S, Tena A, Iwaki H, Ishikawa Y, Schule P, Arn JS, Robson SC, Fishman JA, Sykes M, Sachs DH, Yamada K: Results of gal-knockout porcine thymokidney xeno-grafts. Am J Transplant 9: 2669-2678, 2009
7. Shimizu A, Yamada K, Robson SC, Sachs DH, Colvin RB: Pathologic characteristics of transplanted kidney xenografts. J Am Soc Nephrol 23: 225-223, 2012
8. First MR, Vaidya PN, Maryniak RK, Weiss MA, Munda R, Fidler JP, Penn I, Alexander JW: Proteinuria following transplantation. Correlation with histopathology and outcome. Transplantation 38: 607-612, 1984
9. Reichel H, Zeier M, Ritz E: Proteinuria after renal transplantation: Patho-genesis and management. Nephrol Dial Transplant 19: 301-305, 2004
10. Halimi JM, Matthias B, Al-Najjar A, Laouad I, Chatelet V, Marliere JF, Nivet H, Lebranchu Y: Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 7: 2775-2781, 2007
11. Fernandez-Fresnedo G, Escallada R, Rodrigo E, De Francisco AL, Cotorruelo JG, Sanz De Castro S, Zubimendi JA, Ruiz JC, Arias M: The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 73: 1345-1348, 2002
12. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW3rd: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3: 85ra46, 2011
13. Perosa F, Favoino E, Caragnano MA, Dammacco F: Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107: 1070-1077, 2006
14. Yaoita E, Franke WW, Yamamoto T, Kawasaki K, Kihara I: Identification ofrenal podocytes in multiple species: Higher vertebrates are vimentin positive/lower vertebrates are desmin positive. Histochem Cell Biol 111: 107-115, 1999
15. RoccatelloD, Sciascia S, Rossi D, Alpa M, NarettoC, BaldovinoS, Menegatti E, La Grotta R, Modena V: Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 26: 3987-3992, 2011
16. Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC: Rituximab therapy for type I membranoproliferative glomerulonephritis. Clin Nephrol 77: 290-295, 2012
17. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous ne-phropathy. Kidney Int 73: 117-125, 2008
18. Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N: Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int 22: 906-913, 2009
19. Pescovitz MD, Book BK, Sidner RA: Resolution of recurrent focal seg-mental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354: 1961-1963, 2006
20. Gallon L, Chhabra D: Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropa-thy in a renal transplant patient. Am J Transplant 6: 3017-3021, 2006
21. Damodar A, Mustafa R, Bhatnagar J, Panesar M, Gundroo A, Zachariah M, Blessios G, Tornatore K, Weber-Shrikant E, Venuto R: Use of anti-CD20 antibody in the treatment of post-transplant glomerulonephritis. Clin Transplant 25: 375-379, 2011
22. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J: Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63, 2008
23. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, SchwengerV, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011
24. Garin EH, DiazLN, Mu W, Wasserfall C, ArayaC, Segal M, Johnson RJ: Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol20: 260-266, 2009
25. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Mùller S, Jaffrézou JP, Laurent G: Rituximab antiproliferative effect in B-lym-phoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166-1173, 2004